Central Nervous System

CNS remains among the most active and challenging realms of drug development, focused on significant and growing market opportunities in categories as diverse as Treatment-Resistant Depression and Alzheimer’s Disease. In 2021, we expect data readouts in novel areas such as psilocybin therapeutics and closely watched trials involving anti-amyloid, anti-tau and immune-modulatory therapeutics.
What we’re watching